<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276012</url>
  </required_header>
  <id_info>
    <org_study_id>AC-274</org_study_id>
    <nct_id>NCT04276012</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Cardiovascular Risk Intervention Program in Patients With Schizophrenia (PRISCA)</brief_title>
  <acronym>PRISCA</acronym>
  <official_title>Effectiveness of a Cardiovascular Risk Intervention Program in Patients With Schizophrenia: PRISCA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Pere Roura-Poch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consorci Hospitalari de Vic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to determine the effectiveness of a program which consists of
      multidisciplinary, intensive and individualized interventions, carried out by a group of
      health professionals (psychiatrist, psychologist, mental health nurse, primary care doctors,
      pharmacist), during six-month, to improve the global cardiovascular risk (CVR) in patients
      with schizophrenia. Secondarily, will be analyzed the effectiveness of this program on
      improving the control in four selected cardiovascular risk factors: hypertension,
      hypercholesterolemia, hyperglycaemia and smoking, after 6 months Methods: randomized study
      with parallel assignment in two groups: control and intervention group, six-month follow-up.
      The eligible patients will be 130 adult (≥18 years) outpatients with a current diagnosis of
      schizophrenia who follow-up by health mental network in Catalonia, who presents at least bad
      control in one of the four selected cardiovascular risk factors. The intervention group will
      receive a multidisciplinary and individualized approach (psychoeducational, recommendations
      of life style and diet, medication adherence and changes in pharmacological strategy,
      depending on the individual needs assessing after cardiovascular risk screening. The control
      group will follow the standard management according to the primary care professionals' team.

      Main measurements: the global CVR at baseline and at six-month follow-up through Framingham
      tables calibrated for the Catalan population (Registre Gironí del Cor, REGICOR). Secondary
      measures: they will be determined, at baseline and at six-month follow-up, four
      cardiovascular risk factors as well: hypertension, hypercholesterolemia, hyperglycaemia and
      smoking, according with the latest recommendations of the Program of preventive activities
      and health promotion (PAPPS) of the Spanish Society of Family and Community Medicine. Other
      measures: anthropometric parameters, medication adherence (8-item Morisky Medication
      Adherence Scale (MMAS 8)), Functional Assessment Screening Tool (FAST) and quality of life
      (EQ-5D).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in global cardiovascular risk</measure>
    <time_frame>At six months</time_frame>
    <description>Framingham tables calibrated for the Catalan population (Registre Gironí del Cor, REGICOR). The CVR was stratified into the following groups:&lt;5%, low; 5-9%, moderate; 10-14%, high; and ≥15, very high.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic/diastolic blood pressure</measure>
    <time_frame>At six months</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycated haemoglobin</measure>
    <time_frame>At six months</time_frame>
    <description>Percentage of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cholesterolemia level and other lipids in blood</measure>
    <time_frame>At six months</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stopping tobacco</measure>
    <time_frame>At six months</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will participate in different intervention strategy depending on the individual needs (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual clinical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multifactorial intervention</intervention_name>
    <description>Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        adults (≥18 years of age), outpatient, current diagnostic of schizophrenia, follow-up by
        mental health network in Catalonia, signed informed consent.

        Exclusion Criteria:

        other severe mental illnesses different from schizophrenia, patients with intellectual
        disabilities or clinical acute psychotic relapse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Núria Riera Molist</last_name>
    <phone>+34937027713</phone>
    <email>nriera@chv.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vic Hospital Consortium</name>
      <address>
        <city>Vic</city>
        <state>Catalonia</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Núria Riera-Molist, PhD Student</last_name>
      <phone>+34937027772</phone>
      <email>nriera@chv.cat</email>
    </contact>
    <investigator>
      <last_name>Núria Riera-Molist, PhD Student</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Quintí Foguet-Boreu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santiago García-Eslava, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montse Serra-Millas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montse Assens-Tauste, ND</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pere Roura-Poch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neus Frau-Rosello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estefania Gallego-Peña, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Manel Santos-Lopez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Ayerbe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Guimera-Gallent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Consorci Hospitalari de Vic</investigator_affiliation>
    <investigator_full_name>Dr. Pere Roura-Poch</investigator_full_name>
    <investigator_title>Epidemiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

